Adenosine cyclophosphateCAS# 60-92-4 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 60-92-4 | SDF | Download SDF |
| PubChem ID | 274 | Appearance | Powder |
| Formula | C10H12N5O6P | M.Wt | 329.21 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Solubility | H2O : ≥ 5 mg/mL (15.19 mM) DMSO : < 1 mg/mL (insoluble or slightly soluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol | ||
| SMILES | C1C2C(C(C(O2)N3C=NC4=C3N=CN=C4N)O)OP(=O)(O1)O | ||
| Standard InChIKey | IVOMOUWHDPKRLL-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C10H12N5O6P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(20-10)1-19-22(17,18)21-7/h2-4,6-7,10,16H,1H2,(H,17,18)(H2,11,12,13) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Adenosine cyclophosphate combined with vitamin C treatment of children with viral myocarditis has exact curative effect,and it can improve cardiac function of patients and improve immune function. Combined Puerarin with meglumine adenosine cyclophosphate in treating refractory heart failure is effective and safe. |
| Targets | cAMP | PDE | Histone Methyltransferase | PGE |
| In vivo | Clinical observation on effect of Puerarin combined with meglumine adenosine cyclophosphate in treatment of refractory heart failure[Reference: WebLink]Chinese Journal of Integrated Traditional and Western Medicine in Intentire Critical Care,2003 ,39 (14):3263-79.To explore the clinical effect of Puerarin combined with meglumine Adenosine cyclophosphate in treatment of refractory heart failure. Adenosine cyclophosphate combined with vitamin C treatment of children with viral myocarditis and the effect on cellular immune function[Reference: WebLink]Journal of Hainan Medical University , 2016 ,22 (11) :1112-4.To investigate the curative effect of Adenosine cyclophosphate combined with vitamin C on children with viral myocarditis and its effect on cellular immune function. |
Adenosine cyclophosphate Dilution Calculator
Adenosine cyclophosphate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0376 mL | 15.1879 mL | 30.3757 mL | 60.7515 mL | 75.9394 mL |
| 5 mM | 0.6075 mL | 3.0376 mL | 6.0751 mL | 12.1503 mL | 15.1879 mL |
| 10 mM | 0.3038 mL | 1.5188 mL | 3.0376 mL | 6.0751 mL | 7.5939 mL |
| 50 mM | 0.0608 mL | 0.3038 mL | 0.6075 mL | 1.215 mL | 1.5188 mL |
| 100 mM | 0.0304 mL | 0.1519 mL | 0.3038 mL | 0.6075 mL | 0.7594 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Phloretin
Catalog No.:BCN4128
CAS No.:60-82-2
- Phlorizin
Catalog No.:BCN4126
CAS No.:60-81-1
- Antipyrine
Catalog No.:BCC8834
CAS No.:60-80-0
- Veratramine
Catalog No.:BCN2965
CAS No.:60-70-8
- Methimazole
Catalog No.:BCC3812
CAS No.:60-56-0
- Tetracycline
Catalog No.:BCC9176
CAS No.:60-54-8
- Acetyl-Strophanthidin
Catalog No.:BCC8113
CAS No.:60-38-8
- Acetamide
Catalog No.:BCN4114
CAS No.:60-35-5
- Linoleic acid
Catalog No.:BCN3821
CAS No.:60-33-3
- (6-)ε-Aminocaproic acid
Catalog No.:BCC4888
CAS No.:60-32-2
- Acetylcholine chloride
Catalog No.:BCN2197
CAS No.:60-31-1
- H-Tyr-OH
Catalog No.:BCC3123
CAS No.:60-18-4
- N-Me-DL-Ala-OH.HCl
Catalog No.:BCC2618
CAS No.:600-21-5
- 11Beta-hydroxyprogesterone
Catalog No.:BCN2211
CAS No.:600-57-7
- Oblongine
Catalog No.:BCN4103
CAS No.:60008-01-7
- Glabrene
Catalog No.:BCN6692
CAS No.:60008-03-9
- Chlormethiazole hydrochloride
Catalog No.:BCC6830
CAS No.:6001-74-7
- BOC-L-6-HYDROXYNORLEUCINE
Catalog No.:BCN2360
CAS No.:77611-37-1
- Alizarin 2-methyl ether
Catalog No.:BCN3480
CAS No.:6003-11-8
- GL3
Catalog No.:BCN8180
CAS No.:60037-39-0
- N-Demethylechitamine
Catalog No.:BCN4104
CAS No.:60048-88-6
- Bay 65-1942 free base
Catalog No.:BCC1408
CAS No.:600734-02-9
- Bay 65-1942 HCl salt
Catalog No.:BCC1409
CAS No.:600734-06-3
- Secologanic acid
Catalog No.:BCN8214
CAS No.:60077-46-5
Oral administration of dibutyryl adenosine cyclophosphate improved growth performance in weaning piglets by enhancing lipid fatty acids metabolism.[Pubmed:30182065]
Anim Nutr. 2018 Sep;4(3):260-264.
Dibutyryl Adenosine cyclophosphate (dbcAMP-Ca), an analog of cyclic adenosine monophosphate (cAMP), plays greater roles in regulating physiological activities and energy metabolism than cAMP. The aim of this study was to investigate the effect of oral administration of dbcAMP-Ca on growth performance and fatty acids metabolism in weaning piglets. A total of 14 early weaning piglets (7 +/- 1 d of age, 3.31 +/- 0.09 kg, Landrace x Large White x Duroc) were randomly divided into 2 groups: control group and dbcAMP-Ca group, and the piglets received 7 mL of 0.9% NaCl or 1.5 mg dbcAMP-Ca dissolved in 7 mL of 0.9% NaCl per day for 10 d, respectively. The results showed that the average daily gain (ADG) increased by 109.17% (P < 0.05) in the dbcAMP-Ca group compared with the control group. Besides, dbcAMP-Ca significantly decreased blood high density lipoprotein cholesterol (HDLC) concentration (P < 0.05) and significantly increased blood low density lipoprotein cholesterol (LDLC) concentration (P 0.05) compared with the control group. Further, liver C18:2n6t content significantly increased in dbcAMP-Ca group (P < 0.05) compared with the control group. With the increase of C18:2n6t content, the mRNA expression levels of peroxisome proliferator-activated receptor alpha (PPARalpha) and hormone sensitive glycerol three lipase (HSL), of which genes are related to lipid metabolism, were also significantly increased (P < 0.05 or P < 0.01). All of the results indicated that dbcAMP-Ca improved the ADG, which was probably done by regulating fatty acids metabolism in the liver of weaning piglets.
[Effect of berberine on left ventricular remodeling in renovascular hypertensive rats].[Pubmed:17520837]
Yao Xue Xue Bao. 2007 Mar;42(3):336-41.
The purpose of this study is to evaluate the effects and the underline mechanisms of berberine on the cardiac function and left ventricular remodeling in rats with renovascular hypertension. The renovascular hypertensive model was established by the two-kidney, two-clip (2K2C) method in Sprague-Dawley (SD) rats. Two weeks after surgery, all the operated SD rats were randomly assigned into four groups: (1) renovascular hypertensive model group; (2) berberine 5 mg x kg(-1) group; (3) berberine 10 mg x kg(-1) group; (4) captopril 45 mg x kg(-1) group; and the sham operated rats were used as control. Four weeks after the drugs were administered, the cardiac function was assessed. The ratios of heart weight to body weight (HW/BW), left ventricular weight to body weight (LVW/BW) and right ventricular weight to body weight (RVW/BW) were compared between groups. Coronal sections of the left ventricular tissue (LV) were prepared for paraffin sections, picrosirius red and HE staining was performed. The left ventricular wall thickness (LVWT), interventricular septal thickness (IVST), the parameters of myocardial fibrosis indicated by interstitial collagen volume fraction (ICVF) and perivascular collagen area (PVCA) were assessed. Nitric oxide (NO), Adenosine cyclophosphate (cAMP) and guanosine cyclophosphate (cGMP) concentrations of left ventricular tissue were measured. Berberine 5 mg x kg(-1) and 10 mg x kg(-1) increased the left ventricular +/- dp/dt(max) and HR. Berberine 10 mg x kg(-1) decreased HW/BW and LVW/BW. The image analysis showed that both 5 and 10 mg x kg(-1) of berberine decreased LVWT, ICVF and PVCA, while increased the NO and cAMP contents in left ventricular tissue. Berberine could improve cardiac contractility of 2K2C model rats, and inhibit left ventricular remodeling especially myocardial fibrosis in renovascular hypertension rats. And such effects may partially associate with the increased NO and cAMP content in left ventricular tissue.
